Using placental pathology to prevent recurrent pregnancy complications
Official title: Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project (UPPPP Trial)
Run by Endeavor Health · NCT06004674 · Data updated 2026-11-12
This study is testing if a blood thinner called enoxaparin can help women who have had pregnancy complications in the past have healthier pregnancies this time around.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Endeavor Health Academic / other |
| Locations | 1 site (Evanston, Illinois) |
| Status | Recruiting |
| Started | December 26, 2023 |
| Main results expected | March 2027 |
| Study ends | March 2027 |
| Registry record updated | July 23, 2026 |
| Trial ID | NCT06004674 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women with a history of adverse pregnancy outcomes and maternal vascular malperfusion in a previous pregnancy, currently pregnant with a singleton fetus.
✕Probably not a fit
Patients who are already on anticoagulation therapy or have contraindications to enoxaparin will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot project aims to evaluate whether enoxaparin can prevent recurrent adverse pregnancy outcomes in women who have experienced complications in previous pregnancies, such as miscarriage or preeclampsia. Participants will be randomized into two groups: one receiving enoxaparin and the other receiving standard care. Blood samples will be collected at various stages of the pregnancy to monitor health and treatment effects. The study focuses on patients with maternal vascular malperfusion identified in prior pregnancies to guide treatment in subsequent pregnancies.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of recurrent adverse pregnancy outcomes for affected women.
How similar studies have gone: While similar approaches have been explored, this specific use of placental pathology to guide treatment in subsequent pregnancies is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Eligibility Criteria: Inclusion (must meet all three criteria): 1. Subjects with a prior adverse outcome in a prior pregnancy. Adverse outcome is defined as prior singleton preterm birth ( \< 37 weeks), SGA infant (defined as birthweight \< 10th percentile), preeclampsia with severe features, or stillbirth (fetal demise after 20 weeks gestation), as certified by an obstetrician 2. Patients with maternal vascular malperfusion on pathology from pregnancy with prior adverse pregnancy outcome, as certified by a perinatal placental pathologist 3. Current singleton pregnancy at \<16 6/7 weeks gestational age. Exclusion Criteria: 1. Anticoagulation planned for current pregnancy (including warfarin, enoxaparin, heparin) 2. Known major fetal anomaly 3. Contraindication to enoxaparin: Specifically active major bleeding, known thrombocytopenia (platelets \<100), hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol 4. Chronic kidney disease with eGFR\< 60 5. Known chronic liver disease with baseline AST/ALT \> 3 x upper limit of normal 6. Subjects with mechanical prosthetic heart valves
Where it's running
-
NorthShore University HealthSystem
Evanston, Illinois, United States Recruiting
Study contacts
- Principal investigator: Sunitha Suresh — Endeavor Health
- Study coordinator: Sunitha Suresh
- Email: SSuresh@northshore.org
- Phone: (847) 570-2860
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if PuraStat after Aquablation reduces bleeding and speeds discharge
This study tests whether applying PuraStat after Aquablation can reduce bleeding and allow more patients to go home the same day.
-
Structured social activities to help older adults overcome loneliness
This study tests whether a personalized plan of two hours per week of community activities can help adults 55 and older who feel lonely feel less lonely over six months.
-
Can a handheld nerve monitor detect early ICU weakness in healthy people and ICU patients
This study tests whether a non-invasive nerve monitor (TetraGraph) can spot early signs of ICU-acquired weakness by comparing its readings with standard nerve tests in healthy volunteers and ICU patients.
-
How the type of sedation affects recovery after TAVR
This study will test whether three common sedation approaches (propofol, dexmedetomidine, or midazolam with fentanyl) change how people recover on the first day after transfemoral TAVR.
-
Zinc plus phytase given before botulinum toxin injections for overactive bladder
This trial will test whether a short course of oral zinc plus phytase before botulinum toxin bladder injections helps adult women with overactive bladder go longer without needing another injection over six months.
-
Autonomic Nerve Blockade to Reduce Pain and Nausea After Bariatric Surgery
This study tests whether an autonomic nerve block given during bariatric surgery can lessen pain and nausea and decrease the need for anti-nausea and pain medicines in the first 72 hours after sleeve gastrectomy or gastric bypass.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.